Business
Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun
Dr. Bumpus brings deep experience in scientific innovation and regulatory strategy, while Elaine Sun adds extensive leadership in life sciences finance and
About this update from Recursion Pharmaceuticals, Inc.
[{"type":"text","content":"Dr. Bumpus brings deep experience in scientific innovation and regulatory strategy, while Elaine Sun adds extensive leadership in life sciences finance and corporate strategy.\nSalt Lake City, UT, March 18, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that Namandjé Bumpus, Ph.D, and Elaine Sun have been appointed to Recursion’s Board of Directors, effective as of March 15th.“I am delighted to welcome Elaine and Namandjé to Recursion’s Board,” said Chris Gibson, Ph.D., Recursion Co-Founder and CEO. “As the company continues to grow its clinical pipeline and enhance its platform, our new Board members’ scientific, clinical, business and financial expertise will be an incredible resource in support of our continued success.”Dr. Namandjé N. Bumpus served as the FDA’s Principal Deputy Commissioner until December 31, 2024, after joining the agency in August 2022 as Chief Scientist. As Principal Deputy Commissioner she played a pivotal role in shaping the agency’s strategic direction and driving its day-to-day operations. She worked closely with the FDA Commissioner to spearhead key public health initiatives, strengthening regulatory frameworks, modernizing enterprise systems, and enhancing laboratory testing capabilities. She was also one of the foremost drivers of strategy for integration of AI into regulatory science at the agency. Prior to the FDA, Dr. Bumpus was an endowed professor and chair of the Department of Pharmacology and Molecular Sciences at Johns Hopkins University School of Medicine, where she also served as an associate dean. She earned a Ph.D. in pharmacology from the University of Michigan and completed a postdoctoral fellowship at The Scripps Research Institute. Her prior research has spanned across drug metabolism, drug-induced toxicity, mass spectrometry, and infectious disease pharmacology. Dr. Bumpus has received several honors, including the Presidential Early Career Award, the John J. Abel Award, and the Leon I. Goldberg Award, and is a fellow of the American Association for the Advancement of Science and a member of the National Academy of Medicine.\"I’m proud to join Recursion’s Board and contribute to its innovative approach to drug discovery and development,” said Dr. Bumpus, “I look forward to brin...